Ignite Creation Date:
2025-12-24 @ 10:32 PM
Ignite Modification Date:
2025-12-28 @ 2:10 PM
Study NCT ID:
NCT01292135
Status:
COMPLETED
Last Update Posted:
2014-07-24
First Post:
2011-02-02
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
Sponsor:
Pharmacyclics LLC.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-02
Start Date Type:
None
Primary Completion Date:
2012-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-05
Completion Date Type:
ACTUAL
First Submit Date:
2011-02-02
First Submit QC Date:
None
Study First Post Date:
2011-02-09
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-02-28
Results First Submit QC Date:
None
Results First Post Date:
2014-07-24
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-07-17
Last Update Post Date:
2014-07-24
Last Update Post Date Type:
ESTIMATED